NCE-1 Intelligence & Market Opportunity

Orserdu

Elacestrant

Hormonal Therapy

Tablet

Orserdu is a once-daily selective estrogen receptor degrader (SERD) approved for ER-positive, HER2-negative, ESR1-mutated, advanced or metastatic breast cancer in adults after endocrine therapy.

Approval Date

27-Jan-23

NCE-1 Date

27-Jan-27

NCE Date

27-Jan-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

419

2027

382

2028

164

2029

104

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Elacestrant

Innovator

STEMLINE THERAPEUTICS INC

Dosage Form

Tablet

Strength

EQ 86 mg base, EQ 345 mg base

Therapeutic Category

Hormonal Therapy

Usage

To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets